



# Washington Township Health Care District

2000 Mowry Avenue, Fremont, California 94538-1716 | 510.797.1111

Kimberly Hartz, Chief Executive Officer

## Board of Directors

Jacob Eapen, MD  
William F. Nicholson, MD  
Bernard Stewart, DDS  
Michael J. Wallace  
Jeannie Yee

## BOARD OF DIRECTORS' MEETING

Monday, November 18, 2019 – 6:15 P.M.  
Board Room, 2000 Mowry Avenue

### AGENDA

#### PRESENTED BY:

- |   |  |
|---|--|
| <p><b>I. CALL TO ORDER &amp; PLEDGE OF ALLEGIANCE</b></p> <p><b>II. ROLL CALL</b></p> <p><b>III. COMMUNICATIONS</b></p> <p>A. Oral<br/><i>This opportunity is provided for persons in the audience to make a brief statement, not to exceed three (3) minutes on issues or concerns not covered by the agenda. "Request to Speak" cards should be filled out in advance and presented to the District Clerk. For the record, please state your name.</i></p> <p>B. Written</p> <p><b>IV. CONSENT CALENDAR</b><br/><i>Items listed under the Consent Calendar include reviewed reports and recommendations and are acted upon by one motion of the Board. Any Board Member or member of the public may remove an item for discussion before a motion is made.</i></p> <p>A. Consideration of Budgeted Capital Request:<br/>MALDI-TOF LT/SH Smart Bacterial Identification System (\$316,076.56)</p> <p>B. Consideration of Unbudgeted Capital Request:<br/>Smith and Nephew T-Max II and Spider 2 Shoulder Positioners (\$58,444.00)</p> <p><b>V. REPORT</b></p> <p>A. PG&amp;E Blackout Preparation Report</p> <p><b>VI. CLOSED SESSION</b><br/><i>In accordance with Section 1461, 1462, 32106 and 32155 of the California health &amp; Safety Code and Sections 54962 and</i></p> | <p>Bernard Stewart<br/>Board President</p> <p>Dee Antonio<br/>District Clerk</p> <p>Ed Fayen, Sr. Vice President &amp; Chief Operating Officer<br/>Robert Alfieri, Chief, Facilities</p> <p>Kimberly Hartz<br/>Chief Executive Officer</p> |
|---|--|

Board Meeting Agenda  
November 18, 2019

*54954.5 of the California Government Code, portions of this meeting may be held in closed session.*

- A. Conference with Legal Counsel-Anticipated Litigation pursuant to Government Code section 54956.9(d)(2)
- B. Conference involving a trade secret pursuant to Health & Safety Code section 32106
- C. Conference on personnel matters, Cal Gov. Code Section 54957

**VII. OPEN SESSION**

Report on Closed Session

Bernard Stewart  
Board President

**VIII. ACTION**

- A. Consideration of Claim: Lisha and Edward John A. Capucion

*Motion Required*

**IX. ADJOURNMENT**

Bernard Stewart  
Board President

*In compliance with the Americans with Disabilities Act, if you need assistance to participate in this meeting, please contact the District Clerk at (510) 818-6500. Notification two working days prior to the meeting will enable the District to make reasonable arrangements to ensure accessibility to this meeting.*



---

## Memorandum

**DATE:** November 12, 2019

**TO:** Washington Township Health Care District Board of Directors

**FROM:** Kimberly Hartz, Chief Executive Officer

**SUBJECT: Request for Purchase of Bruker MALDI-TOF LT/SH Smart Bacterial Identification System**

We are recommending moving forward with the purchase of a Matrix-assisted laser desorption ionization time-of-flight mass spectroscopy (MALDI-TOF MS) system in the laboratory at Washington Hospital Healthcare System (WHHS). MALDI-TOF technology replaces traditional microbiology biochemical methodology and will allow the laboratory the ability to decrease the use of sendout laboratories (i.e. ARUP, Quest) to identify bacteria. The Bruker MALDI-TOF Microflex LT/SH Smart System has the largest catalogue of identifiable bacteria and will readily interface with our existing laboratory instrumentation, allowing for easy integration of bacterial identification and antibiotic susceptibility. After detection, MALDI-TOF will allow for a decrease in identification time from 18 hours to as low as 4 hours. Early identification can lead to more appropriate antibiotic selection and quicker clinical decision-making and potential discharge. Some additional advantages of the MALDI-TOF system include decrease in biochemical usage in microbiology, integration of bacterial identification to antibiotic sensitivities on existing Beckman Coulter instrumentation, ability to identify organisms before utilizing a reference lab, and increase drug susceptibility library at WHHS. MALDI-TOF or other molecular testing methods in microbiology are industry standard for hospitals in the Bay Area. Hospitals that use molecular testing include St Rose, El Camino, Santa Clara Valley, Kaiser and UCSF. This request has been reviewed and endorsed by the WHHS Antimicrobial Stewardship Committee which includes Dr. Dianne Martin, Lina Huang, Dr. Muni Barash, Dr. Jevan Tang, and Dr. Herman Chawla.

The following outlines the costs associated with the implementation of this equipment:

Purchase price of Bruker MALDI-TOF analyzer	\$235,000.00
Beckman LabPro MBT Software	\$ 13,125.00
External Contract Labor (IS budget)	\$ 20,000.00
Internal Labor (Lab Validation)	\$ 25,000.00
Tax	\$ 22,951.56
<b>Total Cost of Project:</b>	<b>\$316,076.56</b>

In accordance with District Law, Policies and Procedures, it is requested that the Board of Directors authorize the Chief Executive Officer to proceed with the purchase of the Bruker MALDI-TOF System (Bruker Microflex LT/SH Smart System), Beckman LabPro MBT Software, External Contract Labor, and Internal Labor for an amount not to exceed \$316,076.56. The total amount was included in the Fiscal Year 2019/20 Fixed Asset Capital Budget.



---

# Memorandum

**DATE:** November 14, 2019

**TO:** Kimberly Hartz, Chief Executive Officer

**FROM:** Ed Fayen, Executive Vice President and COO

**SUBJECT:** Capital Purchase – Shoulder Positioners: Smith and Nephew T-Max II and Spider 2

We will have a new surgeon working in our Operating Room who specializes in Total Shoulder Arthroplasty starting in December 2019. He will be utilizing two rooms simultaneously in our Operating Room similar to the process used by Drs. Dearborn and Sah. Since Total Shoulder Arthroplasty is a procedure we have rarely done, we do not have the positioning equipment necessary to handle the high volume that we will experience. The Smith and Nephew T-Max II and Spider 2 are the preferred positioning equipment. Since two rooms will be utilized, we are requesting two complete sets of this equipment. The shoulder positioners are necessary to maneuver and position the shoulder for the optimal surgical approach.

These shoulder positioners were not included in the FY 2020 Capital Budget, but performance of the Total Shoulder Arthroplasty procedure will bring significant additional volume to the institution. The two sets of positioning equipment will cost \$58,444.00.

In accordance with District Law, Policies and Procedures, it is requested that the Board of Directors authorize the Chief Executive Officer to proceed with the purchase of the Smith and Nephew T-Max II and Spider 2 shoulder positioners in the amount of \$58,444.00.



## DEVCO FINANCIAL STATEMENTS

Reporting Period 3

Month of September 2019

*Kimberly Hartz, Chief Executive Officer*

Washington Township Health Care District • Washington Hospital • Institute for Joint Restoration and Research • Sandy Amos RN Infusion Center  
Taylor McAdam Bell Neuroscience Institute • UCSF - Washington Cancer Center • Washington Center for Wound Healing & Hyperbaric Medicine  
Washington Maternal Child Education • Washington on Wheels • Washington Outpatient Diabetes Program • Washington Outpatient Imaging Center  
Washington Outpatient Rehabilitation Center • Washington Outpatient Surgery Center • Washington Prenatal Diagnostic Center  
Washington Radiation Oncology Center • Washington Special Care Nursery • Washington Sports Medicine • Washington Township Medical Foundation  
Washington Urgent Care • Washington Wellness Center • Washington Women's Center



**Washington Township Hospital  
Development Corporation  
Summary Income Statement  
September 2019**

Current Month				Year - To - Date				
Actual	Budget	Favorable/(Unfavorable)		Actual	Budget	Favorable/(Unfavorable)		
		Variance	%			Variance	%	
3,400	3,140	260	8.3%	10,013	9,416	597	6.3%	
362	191	171	89.5%	960	681	279	41.0%	
<b>3,762</b>	<b>3,331</b>	<b>431</b>	<b>12.9%</b>	<b>10,973</b>	<b>10,097</b>	<b>876</b>	<b>8.7%</b>	
				<b>Gross Revenue</b>				
3,943,723	3,899,973	43,750	1.1%	(4) Patient Revenue	12,351,375	12,347,815	3,560	0.0%
886,654	846,361	40,293	4.8%	(5) Other Revenue	2,604,832	2,569,310	35,522	1.4%
<b>4,830,377</b>	<b>4,746,334</b>	<b>84,043</b>	<b>1.8%</b>	<b>(6) Total Gross Revenue</b>	<b>14,956,207</b>	<b>14,917,125</b>	<b>39,082</b>	<b>0.3%</b>
				<b>Deductions</b>				
1,893,246	2,050,211	156,965	7.7%	<b>(7) Total Deductions</b>	<b>6,350,247</b>	<b>6,488,414</b>	<b>138,167</b>	<b>2.1%</b>
48.0%	52.6%	4.6%		Contractual Percentage	51.4%	52.5%	1.1%	
<b>2,937,131</b>	<b>2,696,123</b>	<b>241,008</b>	<b>8.9%</b>	<b>(8) Net Revenue</b>	<b>8,605,960</b>	<b>8,428,711</b>	<b>177,249</b>	<b>2.1%</b>
				<b>Expenses</b>				
863,409	873,205	9,796	1.1%	(9) Purchased Labor	2,635,539	2,665,780	30,241	1.1%
287,037	284,330	(2,707)	(1.0%)	(10) Purchased Benefits	864,739	870,048	5,309	0.6%
328,570	318,131	(10,439)	(3.3%)	(11) Supplies	1,081,516	986,439	(95,077)	(9.6%)
318,122	288,590	(29,532)	(10.2%)	(12) Professional Fees	1,006,908	944,116	(62,792)	(6.7%)
208,190	225,019	16,829	7.5%	(13) Purchased Services	694,636	682,005	(12,631)	(1.9%)
94,418	92,832	(1,586)	(1.7%)	(14) Depreciation and Amort	283,296	279,528	(3,768)	(1.3%)
33,043	26,512	(6,531)	(24.6%)	(15) Utilities	86,624	81,567	(5,057)	(6.2%)
415,190	415,191	1	0.0%	(16) Building Lease	1,248,912	1,241,419	(7,493)	(0.6%)
116,058	129,645	13,587	10.5%	(17) Other Expenses	382,033	393,219	11,186	2.8%
<b>2,664,037</b>	<b>2,653,455</b>	<b>(10,582)</b>	<b>(0.4%)</b>	<b>(18) Total Expenses</b>	<b>8,284,203</b>	<b>8,144,121</b>	<b>(140,082)</b>	<b>(1.7%)</b>
273,094	42,668	230,426	540.0%	<b>(19) Net Operating Income/Loss</b>	<b>321,757</b>	<b>284,590</b>	<b>37,167</b>	<b>13.1%</b>
150,186	80,184	(70,002)	(87.3%)	<b>(20) Minority Interest</b>	<b>247,141</b>	<b>318,502</b>	<b>71,361</b>	<b>22.4%</b>
<b>122,908</b>	<b>(37,516)</b>	<b>160,424</b>	<b>427.6%</b>	<b>(21) Net Income/Loss</b>	<b>74,616</b>	<b>(33,912)</b>	<b>108,528</b>	<b>320.0%</b>